

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.: 37945-0009

Applicant(s): Marianne BRUGGEMANN

Appl. No.: 09/734,613

Examiner: A. Wehbe

Filing Date: December 13, 2000

Group Art Unit: 1632

Title: MURINE EXPRESSION OF A HUMAN IgA LAMBDA LOCUS

RECEIVED

JUL 31 2002

TECH CENTER 1600 2900

**RESPONSE TO OFFICE COMMUNICATION**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Applicants herein respond to the Office communication mailed July 2, 2002 (Paper No. 10). After speaking with Examiner Wehbe on July 26, 2002, it was determined that page 3 of the Amendment filed on May 21, 2002 was missing from the Patent Office's records. Page 3 was faxed to Examiner Wehbe shortly thereafter. An additional copy of the entire Amendment as filed is attached hereto for the Examiner's convenience. Applicants believe this should put them in compliance with 37 CFR §1.121 and 37 CFR §1.821-1.825.

Applicants respectfully request examination on the merits of this application. The examiner is invited to contact the undersigned at (202) 912-2000 should there be any questions.

Respectfully submitted,

Date:

July 29, 2002

By

HELLER EHRMAN WHITE &  
MCAULIFFE  
1666 K Street, NW, Suite 300  
Washington, D.C. 20006  
Phone: (202) 912-2000  
Fax: (202) 912-2020


John P. Isacson  
Attorney for Applicant  
Reg. No.: 33,715

Customer I.D. No. 26633



26633

PATENT TRADEMARK OFFICE



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20503  
www.uspto.gov

APPLICATION NO	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO	CONFIRMATION NO
09 734,613	12/13/2000	Marianne Bruggemann	37945-0009	3627

7590 07/02/2002  
John P. Isacson  
Heller Ehrman White & McAuliffe LLP  
Suite 300  
1666 K. Street, N.W.  
Washington, DC 20006

EXAMINER  
WEHBE, ANNE MARIE SABRINA

ART UNIT	PAPER NUMBER
1632	10

DATE MAILED: 07/02/2002

Please find below and/or attached an Office communication concerning this application or proceeding.

RECEIVED  
JUL 8 1 2002  
TECH. CENTER 1600/2900



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/734,613	12/13/00	Bruggemann	37945-0009

EXAMINER

A.M.S. Wehbé

ART UNIT	PAPER NUMBER
1632	10

RECEIVED  
JUL 29 2002  
TECH CENTER 1600/2900

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application.

This application contains sequence disclosures that are encompassed by the definitions for nucleotide and/or amino acid sequences set forth in 37 CFR 1.821 (a)(1) and (a)(2). However, this application fails to comply with the requirements of 37 CFR 1.821 through 1.825 for the reason(s) set forth on the attached Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures. Specifically, the specification on page 20 contains sequences which are not identified by SEQ ID NOS.

Please note that while applicant's pre-amendment received on 5/2/01 attempted to amend the specification to include SEQ ID NOS for these sequences and further requested the insertion of the substitute sequence listing, this amendment does not comply with 37 CFR 1.121 and has not been entered. In particular, the amendment does not include a clean version of the replacement paragraph/section as required by 37 CFR 1.121 (b)(1)(ii), and/or does not include a marked-up version of the replacement paragraph/section 37 CFR 1.121 (b)(1)(iii). Resubmission of the amendment in the proper format (see the enclosed information flyer on simplified amendment practice) will place the application in compliance with 37 CFR 1.821-1.825.

Any inquiry concerning this communication should be directed to Examiner A.M.S. Wehbé, Ph.D., Art Unit 1632, whose telephone number is (703) 306-9156. Any inquiry of a general nature or relating to the status of this application should be directed to the Technology Center receptionist whose telephone number is (703) 308-0196.

APPLICANT IS GIVEN A ONE MONTH EXTENDABLE PERIOD WITHIN WHICH TO COMPLY WITH THE SEQUENCE RULES, 37 CFR 1.821-1.825. Failure to comply with these requirements will result in ABANDONMENT of this application under 37 CFR 1.821 (g). Extension of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136. In no case may an applicant extend the period for response beyond the six month statutory period. Applicant is requested to return a copy of the attached Notice To Comply with the response.

*[Handwritten signature]*



Application No.: 09/734,613

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☐ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☒ 7. Other: sequences on page 20 are not identified by SEQ ID NOS., see attached letter

**RECEIVED**

JUL 31 2002

**Applicant Must Provide:**

- ☐ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing"
- ☐ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☐ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

For PatentIn software help, call (703) 308-6856

**PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE**